DaVita (DVA)
Health Care · healthcare facilities / dialysis services · NYSE
DaVita is a specialized healthcare provider focused on delivering life-sustaining dialysis and integrated kidney care services to patients with chronic kidney failure.
What DaVita does
DaVita Inc. is a leading provider of dialysis services in the United States, primarily treating patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company operates a vast network of outpatient dialysis centers and provides related laboratory and pharmacy services to support kidney care patients.
Themes: kidney care, chronic disease management, dialysis services
Fundamentals
- Price$176.50 as of 2026-08-24 close
- Market cap$11.3B as of 2026-08-24
- 1-year return+25.7% 2025-08-22 close $140.36 → 2026-08-24 close $176.50
- P/E14.46 as of 2026-08-24
- Net margin+6.0% as of 2026-08-24
- Gross margin+32.4% as of 2026-08-24
- ROE+181.2% as of 2026-08-24
- Debt / equity77.99 as of 2026-08-24
- Revenue growth (YoY)+6.5% as of 2026-08-24
- Revenue CAGR (3y)+5.5% SEC XBRL
- Beta0.35 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How DVA compares in its sector
- price-to-earnings ratiobottom 25% 191 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DVA is not currently in any published Top 10 list. Its scores are below.
Long-term score
50.4 #798 of 1,605 scored · #93 of 195 in Health Care
Valuation 88th (price to earnings 14.5 (within its sector)) and profitability 77th (return on equity 181.2%, operating margin 15.1%); weakest is capital return (18th, consecutive years of dividend increases 0 years).
Short-term score
33.9 #1480 of 1,698 scored · #213 of 236 in Health Care
Volume and participation 48th: trading volume is about normal versus its 30-day average; catalysts 48th: open-market insider buys in 90 days 9, the analyst consensus rating is unchanged since the prior reading; weakest is trend 18th: a strong downtrend, with sellers in control.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
How DaVita looks technically
DaVita (DVA) is trading 9.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 111 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 28.7% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 9.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $213.85 | $213.85 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $160.69 | $160.69 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 111 trading days ago — a "golden cross", a bullish long-term signal | 111 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 41, with sellers in control | 40.8 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 28, in oversold territory (below 30) | 28.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($171.40 to $208.35) — its "stochastic" reading is 14 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 13.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $247.49 | $247.49 |
|---|---|---|
| From the 52-week high | it is 28.7% below its 52-week high (its highest price of the past year) | -28.7% |
| Above the 52-week low | it is 74.8% above its 52-week low (its lowest price of the past year) | +74.8% |
| Below the 52-week high | it is 28.7% below its highest point of the past year | 28.7% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $247.49 (set on 2026-08-03) | $247.49 |
| Given back of the 52-week move | over the past year its closes ranged ($103.87 to $240.96), and it has given back around half of its rise from last year’s low — 47% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $151.85 to $156.24. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 47.0% |
| From the all-time high | it is 28.7% below its all-time high | -28.7% |
| Nearest price level | it is trading 1.0% below a resistance level at $178.19 — a price it turned at three times since 2025-01-31, most recently on 2026-08-07. Since 2024-08-26 it has 12 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.0% |
| All-time low | its lowest closing price on record is $20.48 (set on 2008-11-21) | $20.48 |
| Above the all-time low | it is 761.8% above its all-time low | +761.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 96% of the past ~6 months) | 96th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.40 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.40 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $143.56 and $249.87 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $143.56 – $196.72 – $249.87 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 2.5 daily ranges above its 200-day average price (9.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.29× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-24 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 10.0% below the previous close 13 sessions ago and has not traded back through the level it left behind at 227.99 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.0% |
| Gap filled | a 2.4% gap down opened on 2026-08-04 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 14 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 28.4 percentage points (the stock lost 25.0% while the market gained 3.3%) | -28.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 13.5 percentage points (the stock lost 11.1% while the market gained 2.4%) | -13.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 5.9 percentage points (the stock gained 17.0% while the market gained 11.1%) | +5.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 7.4 percentage points (the stock gained 25.7% while the market gained 18.3%) | +7.4% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, its RSI momentum gauge is oversold (a beaten-down reading), outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.9% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 16.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -8.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 5% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $168.05 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +5.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $188.81 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | -6.5% |
Price levels it has turned at before
DVA last closed at $176.50 on 2026-08-24. Since 2024-08-26 it has turned at 12 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $178.19 | Resistance | 1.0% above the last close | turned there three times · 2025-01-31 to 2026-08-07 |
| $168.35 | Support | 4.6% below the last close | turned there four times · 2024-09-19 to 2025-02-06 |
| $159.33 | Support | 9.7% below the last close | turned there twice · 2024-09-24 to 2026-03-02 |
| $156.72 | Support | 11.2% below the last close | turned there six times · 2024-12-27 to 2026-04-23 |
| $202.57 | Resistance | 14.8% above the last close | turned there twice · 2026-05-12 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · beating the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.38 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$218.43 range $165.00 – $270.00; median $220.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DVA
- Consensus EPS estimate$3.58 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant reliance on government reimbursement programs like Medicare and Medicaid.","Exposure to potential legislative or regulatory changes affecting the healthcare industry and dialysis reimbursement rates.","High levels of indebtedness and related debt service obligations."]
What changed in the latest 10-Q
AI-assisted comparison of DVA's 10-Q filed 2026-05-05 against the prior one filed 2025-10-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'cyber incident' as shorthand term alongside full references (filed 2026-05-05)
- Added language about 'impact of the Comprehensive Kidney Care Contracting model and home based dialysis' in VBC/IKC implementation bullet (filed 2026-05-05)
- Added reference to 'Middle East' as specific example of global political volatility (filed 2026-05-05)
- Added phrase 'we have in the past, and currently are, conducting on a concurrent basis' regarding commercial payor negotiations (filed 2026-05-05)
- Added language about 'technologies that utilize artificial intelligence' in information systems bullet (filed 2026-05-05)
- Removed:
- Removed specific reference to 'federal government shutdown' from cybersecurity incident opening statement (filed 2026-05-05)
- Removed reference to 'Medicare Advantage (MA)' definition in parentheses from opening statement, now uses 'MA' abbreviation only (filed 2026-05-05)
- Removed reference to 'federal government shutdown' from mix expectation risks paragraph (filed 2026-05-05)
- Removed reference to 'federal government shutdown' from laws and regulations paragraph (filed 2026-05-05)
- Removed 'and adjustment methodologies' language after 'MA benchmark structure' (filed 2026-05-05)
- Removed full bullet point about ability to 'attract, retain and motivate teammates' and related labor disruption risks that appeared in older filing (filed 2026-05-05)
- Reworded:
- Changed 'the impact of global events and political or governmental volatility, including in the Middle East' from prior version that said 'the impact of global events and political or governmental volatility' without Middle East specification (filed 2026-05-05)
- Changed 'the continuing impact of infectious diseases' to 'the impact of infectious diseases or other adverse conditions' (filed 2026-05-05)
- Reordered risks in external conditions bullet: moved 'continued increased competition from dialysis providers and others' to earlier position and expanded it (filed 2026-05-05)
- Changed 'potential changes in or new laws, regulations or requirements' to 'laws, regulations or requirements applicable to us or changes thereto' (filed 2026-05-05)
- Changed commercial payor bullet from 'or as a result of payors implementing restrictive plan designs' to include additional language 'or as a result of payors implementing restrictive plan designs or resulting from negotiations with large commercial payors that we have in the past, and currently are, conducting on a concurrent basis' (filed 2026-05-05)
- Notes:
- Text appears truncated at end of both filings; comparison is based on available text only
- Older filing shows 23 page number while newer shows 18, suggesting different document lengths or formatting
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($37M) — 1 selling insider
- Last 90 days0 buys · 5 sells ($54M) — 3 selling insiders
- Last 180 days0 buys · 11 sells ($254M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-31. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DVA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for DVA from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
7 institutional 13F filers reported holding DVA as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 7
- Reported shares held 35,368,088
- Reported value $5,435,721,458
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DVA had 4,284,225 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DVA had 6.72% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.51 days to cover at the same settlement.
- Reported short interest (shares) 4,284,225
- Short interest (% of shares outstanding) 6.72%
- Prior settlement (shares) 4,497,611
- Reported change -4.74%
- Days to cover (reported) 7.51
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Fresenius Medical Care (FMS)
- Baxter International (BAX)
- U.S. Renal Care
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DVA vs…
DaVita is found in…
DVA ranks in…
Frequently asked questions
What does DaVita (DVA) do?
DaVita Inc. is a leading provider of dialysis services in the United States, primarily treating patients with end-stage renal disease (ESRD) and chronic kidney disease (CKD). The company operates a vast network of outpatient dialysis centers and provides related laboratory and pharmacy services to support kidney care patients.
What sector is DaVita (DVA) in?
DaVita (DVA) is classified in the Health Care sector. Its industry is healthcare facilities / dialysis services. It trades on NYSE.
Who are DaVita's (DVA) competitors?
Notable peers of DaVita (DVA) include Fresenius Medical Care, Baxter International and U.S. Renal Care. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in DVA?
Yes — we hold 1 matched STOCK Act disclosure for DVA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is DaVita (DVA) overbought or oversold right now?
DaVita (DVA) is currently in oversold territory (its 14-day RSI is 28, below 30) (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DVA come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.